Radiopharmaceutical developer Neoprobe has secured $10 million in debt financing from specialty finance firm Hercules Technology Growth Capital.
Neoprobe said the financing will boost its cash position with limited dilution of investor equity. The first funding, of $7 million, closed on December 29 in the form of a secured note. A second funding of $3 million will be made available when Neoprobe's Lymphoseek product receives U.S. market clearance.
